share_log

B of A Securities Maintains Underperform on Enfusion, Raises Price Target to $9

B of A Securities Maintains Underperform on Enfusion, Raises Price Target to $9

Bof A证券因注入而表现不佳,将目标股价上调至9美元
Benzinga ·  03/13 08:10

B of A Securities analyst Koji Ikeda maintains Enfusion (NYSE:ENFN) with a Underperform and raises the price target from $8 to $9.

B of A Securities分析师池田浩司维持Enfusion(纽约证券交易所代码:ENFN)的表现不佳,并将目标股价从8美元上调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发